Skip to content
Stocks News
Enter Ticker Symbol
  • Home
  • FEATURED COMPANY
  • ANALYST COVERAGE
  • NEWS
  • SUBSCRIBE
  • CONTACT

ANALYST COVERAGE

ubs-maintains-neutral-on-norwegian-cruise-line-holdings-ltd-(nclh)-march-2026

UBS Maintains Neutral on Norwegian Cruise Line Holdings Ltd (NCLH) March 2026

Mar 4, 2026

UBS maintained a Neutral rating on Norwegian Cruise Line Holdings Ltd. (NCLH) on March 03, 2026 after calling…

Read more
brookline-capital-maintains-buy-on-intellia-therapeutics-inc-(ntla)-march-2026

Brookline Capital Maintains Buy on Intellia Therapeutics Inc (NTLA) March 2026

Mar 4, 2026

The NTLA analyst rating was maintained at Buy by Brookline Capital on March 03, 2026, and the firm…

Read more
ubs-maintains-buy-on-burl-(burlington-stores,-inc.)-march-03-2026

UBS Maintains Buy on BURL (Burlington Stores, Inc.) March 03 2026

Mar 4, 2026

UBS maintained a Buy rating on Burlington Stores, Inc. (BURL) on March 03, 2026. This UBS action underlines…

Read more
needham-upgrades-core-scientific-(corz)-to-buy-on-march-03,-2026

Needham Upgrades Core Scientific (CORZ) to Buy on March 03, 2026

Mar 4, 2026

Get analyst ratings, AI forecasts, and market updates in your inbox every morning. 12% average open rate and…

Read more
jefferies-maintains-buy-on-sarepta-therapeutics-(srpt)-march-03,-2026

Jefferies Maintains Buy on Sarepta Therapeutics (SRPT) March 03, 2026

Mar 4, 2026

Jefferies on March 03, 2026 maintained a Buy on Sarepta Therapeutics, Inc. (SRPT), calling the stock a potential…

Read more
btig-maintains-buy-on-psfe-(paysafe-limited)-march-03,-2026,-pt-cut-to-$10

BTIG Maintains Buy on PSFE (Paysafe Limited) March 03, 2026, PT Cut to $10

Mar 4, 2026

BTIG maintained a Buy rating on PSFE on March 03, 2026, while lowering the price target to $10.…

Read more
guggenheim-maintains-buy-on-sportradar-group-ag-(srad)-march-3-2026

Guggenheim Maintains Buy on Sportradar Group AG (SRAD) March 3 2026

Mar 4, 2026

Guggenheim maintained a Buy rating on Sportradar Group AG (SRAD) on March 3 2026, leaving the SRAD analyst…

Read more
btig-maintains-buy-on-sophia-genetics-sa.-(soph)-march-03,-2026

BTIG Maintains Buy on SOPHiA GENETICS S.A. (SOPH) March 03, 2026

Mar 3, 2026

BTIG maintained its Buy rating on SOPHiA GENETICS S.A. (SOPH) on March 03, 2026, giving investors continuity on…

Read more
this-amylyx-pharmaceuticals-analyst-begins-coverage-on-a-bullish-note;-here-are-top-4-initiations-for-tue

This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tue

Mar 3, 2026

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…

Read more
cowen-downgrades-arcellx,-inc.-(aclx)-to-hold-on-march-2,-2026

Cowen Downgrades Arcellx, Inc. (ACLX) to Hold on March 2, 2026

Mar 3, 2026

On March 02, 2026 TD Cowen downgraded Arcellx, Inc. to Hold, creating a new ACLX analyst rating update…

Read more
morgan-stanley-upgrades-roku-(roku,-inc.)-to-overweight-march-02,-2026

Morgan Stanley Upgrades ROKU (Roku, Inc.) to Overweight March 02, 2026

Mar 3, 2026

On March 02, 2026 Morgan Stanley upgraded Roku, Inc. (ROKU) to Overweight, marking the latest change in the…

Read more
stephens-upgrades-first-american-financial-(faf)-to-overweight-mar-2-2026

Stephens upgrades First American Financial (FAF) to Overweight Mar 2 2026

Mar 3, 2026

Stephens upgraded First American Financial Corporation (FAF) from Buy to Overweight on March 2, 2026. The FAF analyst…

Read more
  1. Pages:
  2. «
  3. 1
  4. ...
  5. 18
  6. 19
  7. 20
  8. 21
  9. 22
  10. 23
  11. 24
  12. ...
  13. 377
  14. »

Posts pagination

Newer posts Page 1 … Page 21 … Page 377 Older posts

The content presented on this site is intended solely for entertainment purposes and should not be construed as an invitation to engage in the purchase or sale of securities. Each content provider featured on 10x Wealth Report brings a unique perspective and predisposition, which may not necessarily align with that of 10x Wealth Report. It is crucial to recognize that 10x Wealth Report is not a registered financial advisor or firm. Read More full disclaimer

CATEGORIES

  • FEATURED COMPANY
  • NEWS
  • ANALYST COVERAGE
  • Special Post
  • CONTACT
  • SUBSCRIBE
  • Privacy Policy
  • Terms or Service
  • Disclaimer

CONNECT & FOLLOW

© 10x Wealth Report Copyright 2024.